BGB-11417

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
260 patients (estimated)
Sponsors
BeiGene
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1672
NCT Identifier
NCT04771130

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.